Predict your next investment

Incubator/Accelerator
BUSINESS PRODUCTS & SERVICES | Education & Training (business)
biocity.co.uk

See what CB Insights has to offer

Investments

21

Partners & Customers

6

About BioCity

BioCity is a bioscience incubation specialist with locations in the East Midlands (BioCity and Medicity in Nottingham), the North West (BioHub at Alderley Park), and Scotland (BioCity Scotland at Newhouse). The company was originally founded by the University of Nottingham and Nottingham Trent University.On April 26th, 2021, BioCity merged with We are Pioneer Group. Terms of the transaction were not disclosed.

BioCity Headquarter Location

Pennyfoot Street

Nottingham, England, NG1 1GF,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BioCity News

Drugs research firm opens multi-million pound East Mids lab space to support more than 150 scientists

Apr 26, 2022

Drugs research firm opens multi-million pound East Mids lab space to support more than 150 scientists Charnwood Molecular has moved to a single site from its previous locations in Loughborough and at BioCity in Nottingham 03:00, 26 APR 2022 Charnwood Molecular on the Charnwood Campus in Loughborough Sign up to FREE email alerts from BusinessLive - National - our round-up of the headlines that matter every morning Something went wrong, please try again later.Invalid Email Subscribe We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info Thank you for subscribing!We have more newsletters Show me See our privacy notice A pharmaceutical research contractor has unveiled new lab space which will support the work of more than 150 scientists. Charnwood Molecular has invested millions in the facilities on the Charnwood Campus in Loughborough . The life-science campus on the outskirts of the town was originally as a vast research site for AstraZeneca. It was sold on a decade ago and is home to a number of companies and part of the recently established Loughborough and Leicester Science and Innovation Enterprise Zone. Charnwood Molecular said its investment in the site addressed a national need for specialist bio-chemistry facilities to drive potentially life-saving research into new drugs. The project was supported by £3.4 million from the Leicester and Leicestershire Enterprise Partnership (LLEP) in partnership with Charnwood Borough Council. The funding helped recommission 57,000 sq ft of unused medical lab space, quadrupling Charnwood Molecular’s capacity and supporting further expansion. It has allowed the business to move to a single site from its previous locations in Loughborough and at BioCity in Nottingham. Charnwood Molecular was founded in 1998 as a chemistry spin-out from Loughborough University, and was acquired in 2019 by private equity group Synova. Founder and chief executive Prof Steve Allin said: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector.” Charnwood Campus became the UK’s first Life Science Opportunity Zone in 2017, and was designated an Enterprise Zone site in the same year. Both bring in State support and are part of the Government’s wider industrial strategy to support business and local economic growth. Gosia Khrais, commercial and marketing director at Charnwood Campus, said: “This is another milestone in our ambitious plans to become the leading science, innovation and technology park in the UK. “Charnwood Molecular is rapidly expanding, employing locally and is an outstanding addition to our family of highly successful contract research and manufacturing organisations.” Andy Reed OBE, interim chair of the LLEP board, said: “Through effective use of local resources, such as those at Charnwood Campus, we are building a productive and innovative economy at the cutting edge of science, which will support the health of people around the world. “By investing in projects such as Charnwood Molecular, we are helping to create high-quality jobs to add to the 900 already created on Charnwood Campus since its designation as an Enterprise Zone site.” Coun Tom Barkley, deputy leader of Charnwood Borough Council, said: “I welcome this investment, as not only will it create jobs but it also adds to Charnwood’s growing reputation as being at the centre of innovation. “It’s also another great example of how the Loughborough and Leicester Science and Innovation Enterprise Zone is helping to attract global businesses to the region.” Read More

BioCity Investments

21 Investments

BioCity has made 21 investments. Their latest investment was in NanoSyrinx as part of their Seed VC - II on July 7, 2021.

CBI Logo

BioCity Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/19/2021

Seed VC - II

NanoSyrinx

$8.5M

No

6

4/20/2021

Series A

Rinri Therapeutics

$14M

No

1

4/8/2021

Seed VC - II

Maxwellia

$4.4M

Yes

3

2/2/2021

Seed VC

Subscribe to see more

Subscribe to see more

10

12/15/2020

Seed - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/19/2021

4/20/2021

4/8/2021

2/2/2021

12/15/2020

Round

Seed VC - II

Series A

Seed VC - II

Seed VC

Seed - III

Company

NanoSyrinx

Rinri Therapeutics

Maxwellia

Subscribe to see more

Subscribe to see more

Amount

$8.5M

$14M

$4.4M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

3

10

10

BioCity Partners & Customers

6 Partners and customers

BioCity has 6 strategic partners and customers. BioCity recently partnered with Waters on January 1, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

1/6/2016

Partner

United States

Waters and BioCity to Establish an Open Access Analytical Laboratory in the BioHub at Alderley Park UK

`` Engaging with scientists in the BioHub at Alderley Park provides a unique opportunity to work and partner with customers , given the geographic proximity of Waters Corporation ' Wilmslow location .

1

1/6/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/18/2013

Licensor

United Kingdom

Subscribe to see more

Subscribe to see more

10

10/4/2013

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

4/9/2012

Client

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

1/6/2016

1/6/2016

11/18/2013

10/4/2013

4/9/2012

Type

Partner

Partner

Licensor

Partner

Client

Business Partner

Country

United States

United States

United Kingdom

United Kingdom

United Kingdom

News Snippet

Waters and BioCity to Establish an Open Access Analytical Laboratory in the BioHub at Alderley Park UK

`` Engaging with scientists in the BioHub at Alderley Park provides a unique opportunity to work and partner with customers , given the geographic proximity of Waters Corporation ' Wilmslow location .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

BioCity Team

2 Team Members

BioCity has 2 team members, including current Chief Executive Officer, Toby Reid.

Name

Work History

Title

Status

Sherif Fahmy

Founder

Current

Toby Reid

Chief Executive Officer

Current

Name

Sherif Fahmy

Toby Reid

Work History

Title

Founder

Chief Executive Officer

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.